VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 8, 2026

Stock Comparison

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. vs Eli Lilly and Company

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.

600809 · Shanghai Stock Exchange

Market cap (USD)$218.5B
Gross margin (TTM)76.1%
Operating margin (TTM)44.3%
Net margin (TTM)32.7%
SectorConsumer
IndustryBeverages - Wineries & Distilleries
CountryCN
Data as of2025-12-30
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Shanxi Xinghuacun Fen Wine Factory Co., Ltd.'s moat claims, evidence, and risks.

View 600809 analysis

Eli Lilly and Company

LLY · New York Stock Exchange

Market cap (USD)$935.6B
Gross margin (TTM)83%
Operating margin (TTM)43.9%
Net margin (TTM)31%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-01-05
Moat score
66/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.

View LLY analysis

Comparison highlights

  • Moat score gap: Eli Lilly and Company leads (66 / 100 vs 57 / 100 for Shanxi Xinghuacun Fen Wine Factory Co., Ltd.).
  • Segment focus: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 2 segments (73.7% in Mid-to-High Priced Liquor (>= RMB130/L)); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
  • Moat breadth: Shanxi Xinghuacun Fen Wine Factory Co., Ltd. has 5 moat types across 2 domains; Eli Lilly and Company has 5 across 2.

Primary market context

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.

Mid-to-High Priced Liquor (>= RMB130/L)

Market

China premium baijiu (with focus on light-aroma baijiu) and mid-to-high priced spirits

Geography

China

Customer

Consumers and corporate/banquet demand via distributor/retail channels

Role

Brand owner / distiller / wholesaler-distributor orchestrator

Revenue share

73.7%

Eli Lilly and Company

Cardiometabolic Health

Market

Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)

Geography

Global

Customer

Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels

Role

Drug developer, manufacturer, and marketer

Revenue share

65.5%

Side-by-side metrics

Shanxi Xinghuacun Fen Wine Factory Co., Ltd.
Eli Lilly and Company
Ticker / Exchange
600809 - Shanghai Stock Exchange
LLY - New York Stock Exchange
Market cap (USD)
$218.5B
$935.6B
Gross margin (TTM)
76.1%
83%
Operating margin (TTM)
44.3%
43.9%
Net margin (TTM)
32.7%
31%
Sector
Consumer
Healthcare
Industry
Beverages - Wineries & Distilleries
Drug Manufacturers - General
HQ country
CN
US
Primary segment
Mid-to-High Priced Liquor (>= RMB130/L)
Cardiometabolic Health
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
57 / 100
66 / 100
Moat domains
Demand, Supply
Legal, Supply
Last update
2025-12-30
2026-01-05

Moat coverage

Shared moat types

Learning Curve Yield

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. strengths

Brand TrustDistribution ControlPreferential Input AccessScale Economies Unit Cost

Eli Lilly and Company strengths

IP Choke PointCapacity MoatOperational ExcellenceCompliance Advantage

Segment mix

Shanxi Xinghuacun Fen Wine Factory Co., Ltd. segments

Full profile >

Mid-to-High Priced Liquor (>= RMB130/L)

Oligopoly

73.7%

Other Liquor (value-tier baijiu and other spirits)

Competitive

25.9%

Eli Lilly and Company segments

Full profile >

Cardiometabolic Health

Oligopoly

65.5%

Oncology

Competitive

19.4%

Immunology

Competitive

9.8%

Neuroscience

Competitive

3.3%

Other

Competitive

2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.